WEST LAFAYETTE, IN--(Marketwire - December 20, 2011) - Bioanalytical Systems, Inc. (NASDAQ: BASI) (BASi) today announced financial results for the fourth quarter and fiscal year ended September 30, 2011.
Fiscal 2011 Results
Net income for fiscal 2011 ended September 30, 2011 increased to $543,000. This compares to a net loss for fiscal 2010 of $2,691,000. Revenue increased 15.2% for fiscal 2011 to $33,144,000 from $28,781,000 for fiscal 2010, and gross margin improved to 31.7% versus 25.5%.
“Fiscal 2011 was BASi’s first profitable year since fiscal 2007,” said President and Chief Executive Officer Anthony Chilton, “and we are optimistic that the company will deliver further revenue and earnings growth in fiscal 2012.”
During fiscal 2011, BASi paid down $1,000,000 of long term debt and closed an oversubscribed public offering for $5,506,000 of units consisting of convertible preferred shares and warrants to purchase common shares. Accounting for the value of the warrants and the preferred shares in the third quarter and first nine months of fiscal 2011 resulted in a one-time deemed dividend to preferred stockholders of $3,277,000, which was deducted from net earnings to compute GAAP earnings per share. Additionally, the Company immediately charged $991,080, the payment-in-kind dividends payable to the preferred stockholders, against net earnings to compute GAAP earnings per share. This resulted in a GAAP loss per share of $0.66 for fiscal 2011, compared to a net loss per share of $0.55 for fiscal 2010.
Excluding the deemed dividend to preferred shareholders and the preferred dividend, diluted net income per share would have been $0.09 for fiscal 2011. Management considers the income available to common shareholders and earnings per share exclusive of the dividends to be a useful measure in evaluating the operating results of BASi. A reconciliation of GAAP to non-GAAP financial measures is provided in the table attached to this press release.
Fourth Quarter Results
For the fourth quarter ended September 30, 2011, revenue increased 10.1% to $8,153,000 compared to $7,405,000 for the fourth quarter of fiscal 2010. Primarily due to the mix of services provided and unusually high general and administrative expense, the net loss for the fourth quarter of fiscal 2011 was $668,000, or $0.10 per share, compared to a net loss of $279,000, or $0.06 per share, for the fourth quarter of fiscal 2010.
Balance Sheet Highlights
At September 30, 2011, BASi reported cash and cash equivalents of $2,963,000, working capital of $526,000, total long-term obligations of $6,913,000, and shareholders’ equity of $15,586,000, or $2.26 per outstanding share. At September 30, 2010, cash and cash equivalents were $1,422,000, the working capital deficiency was $3,342,000, total long-term obligations were $7,100,000, and shareholders’ equity was $10,667,000, or $2.17 per outstanding share.
CEO Comments
President and CEO Chilton said, “We generated cash and delivered solid revenue growth and substantially improved bottom-line performance in fiscal 2011 despite a difficult economic environment and delays in certain projects. While business conditions remain challenging, well-established trends in our industry clearly indicate that new drug discovery and development will rely increasingly on outsourcing in the years ahead. As a provider of contract research services for more than 35 years, BASi is positioned to take advantage of these trends by expanding our business with the growing population of small biotech and pharmaceutical companies that have become a major force in new drug discovery, even as we enhance our historically close relationships with major pharmaceutical clients.
“We expanded our sales staff and increased selling expenses by 17% in fiscal 2011 versus prior year in support of this growth strategy, which helped us add more than 25 new accounts to our client roster in fiscal 2011. We also are seeking to expand our service offerings through accretive acquisitions if appropriate opportunities become available. We are confident that we are on the right track to deliver further growth and enhance shareholder value.”
Earnings Conference Call
BASi has scheduled a conference call at 11:00 a.m. EST this morning. To participate, dial 866.314.4483, passcode #70971936 five minutes before the start of the call. A simultaneous webcast may be accessed from the Investors tab at www.BASinc.com. The webcast will be available for replay after 2:00 p.m. EST, at this same Internet address. For a telephone replay, dial 888.286.8010, passcode #87679684 after 2:00 p.m. EST.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.
[SEE BELOW FOR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS]
BIOANALYTICAL SYSTEMS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts)(Unaudited) Three Months Ended Twelve Months Ended September 30, September 30, -------------------- -------------------- 2011 2010 2011 2010 --------- --------- --------- --------- Service revenue $ 6,287 $ 5,772 $ 25,613 $ 21,864 Product revenue 1,866 1,633 7,531 6,917 --------- --------- --------- --------- Total revenue 8,153 7,405 33,144 28,781 Cost of service revenue 5,135 4,711 19,679 18,574 Cost of product revenue 770 713 2,959 2,874 --------- --------- --------- --------- Total cost of revenue 5,905 5,424 22,638 21,448 Gross profit 2,248 1,981 10,506 7,333 Operating expenses: Selling 846 607 3,121 2,665 Research and development 184 112 534 546 General and administrative 1,600 1,289 5,564 6,119 --------- --------- --------- --------- Total operating expenses 2,630 2,008 9,219 9,330 Operating income (loss) (382) (27) 1,287 (1,997) Interest expense (233) (242) (706) (1,028) Other income (expense) (3) 1 12 1 --------- --------- --------- --------- Income (loss) before income taxes (618) (268) 593 (3,024) Income tax expense (benefit) 50 11 50 (333) --------- --------- --------- --------- Net income (loss) $ (668) $ (279) $ 543 $ (2,691) Less: Deemed dividend on Series A preferred shares -- -- (3,277) -- Less: Preferred stock dividends -- -- (991) -- --------- --------- --------- --------- Net income (loss) attributable to common shareholders $ (668) $ (279) $ (3,725) $ (2,691) ========= ========= ========= ========= Basic net income (loss) per share $ (0.10) $ (0.06) $ (0.66) $ (0.55) ========= ========= ========= ========= Diluted net income (loss) per share $ (0.10) $ (0.06) $ (0.66) $ (0.55) ========= ========= ========= ========= Weighted common shares outstanding: Basic 6,913 4,915 5,667 4,915 Diluted 6,913 4,915 5,667 4,915 BIOANALYTICAL SYSTEMS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) September 30, September 30, 2011 2010 -------------- -------------- Assets Current assets: Cash and cash equivalents $ 2,963 $ 1,422 Accounts receivable Trade 4,073 3,670 Unbilled revenues and other 1,116 1,298 Inventories 1,636 1,673 Deferred tax asset 116 -- Refundable income taxes -- 16 Prepaid expenses 585 555 -------------- -------------- Total current assets 10,489 8,634 Property and equipment, net 20,399 19,439 Goodwill 1,383 1,383 Intangible assets, net 54 84 Debt issue costs 75 123 Other assets 62 80 -------------- -------------- Total assets $ 32,462 $ 29,743 ============== ============== Liabilities and shareholders’ equity Current liabilities: Accounts payable $ 1,764 $ 1,911 Accrued expenses 1,762 1,848 Customer advances 3,571 4,582 Income tax accruals 56 30 Deferred income taxes 116 -- Revolving line of credit 1,346 1,195 Fair value of interest rate swaps -- 31 Current portion of capital lease obligation 613 524 Current portion of long-term debt 735 1,855 -------------- -------------- Total current liabilities 9,963 11,976 Capital lease obligation, less current portion 1,071 623 Long-term debt, less current portion 5,842 6,477 Shareholders’ equity: Preferred shares, authorized 1,000,000 shares, no par value: 2,135 Series A shares at 1,000 stated value issued and outstanding at June 30, 2011 and none at September 30, 2010 2,135 -- Common shares, no par value: Authorized 19,000,000; shares issued and outstanding 6,912,511 at June 30, 2011 and 4,915,318 at September 30, 2010 1,698 1,191 Additional paid-in capital 19,408 13,357 Accumulated deficit (7,706) (3,981) Accumulated other comprehensive income 51 100 -------------- -------------- Total shareholders’ equity 15,586 10,667 -------------- -------------- Total liabilities and shareholders’ equity $ 32,462 $ 29,743 ============== ============== BIOANALYTICAL SYSTEMS, INC. DILUTED NET INCOME PER SHARE, EXCLUSIVE OF PREFERRED DIVIDENDS (In thousands, except per share amounts) Twelve Months Ended September 30, 2011 -------------- GAAP basic net income (loss)applicable to common shareholders: Net income $ 543 Less: Deemed dividend for Series A Preferred Shares (3,277) Less: Preferred dividends (991) -------------- GAAP net loss applicable to common shareholders $ (3,725) ============== Diluted net income per share, exclusive of the preferred dividends: GAAP net loss applicable to common shareholders $ (3,725) Plus: Deemed dividend for Series A preferred shares 3,277 Plus: Preferred dividend 991 -------------- Adjusted net income applicable to common shareholders $ 543 ============== GAAP diluted weighted average common shares outstanding 5,667 Plus: Incremental shares from assumed conversions Series A preferred shares 526 Warrants -- Stock options 90 -------------- Adjusted diluted weighted average common shares outstanding 6,283 -------------- Diluted net income per share, exclusive of the deemed dividend $ 0.09 ==============
